Adjuvant Activity of Bursal Pentapeptide-(III-V) in Mice Immunized with the H9N2 Avian Influenza Vaccine

Zhou, Jiangfei; Cong, Zhen; Liu, Zhixin; Liu, Yongqing; Cai, Kairui; Shen, Tengfei; Liao, Chengshui; Wang, Chen

doi:10.2174/0929866525666180806110928

Cited by 11 publications

(12 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A conserved amino sequence containing both T and B cell epitopes of the H9N2 AIV haemagglutinin (HA) protein (GNCVVQCQTERGGLN) was first selected as the antigen epitope by immunoinformatics analysis, and the epitope peptide was then conjugated to appropriate adjuvants to enhance the immune response by the transfer and controlled release of antigens (35). Our previous studies have shown that BPP-V and BP-IV can be used as immune adjuvants in combination with the commercial H9N2 AIV inactivated vaccine to enhance humoral and cellular immune responses (17,18). Therefore, BPP-V and BP-IV were conjugated to synthesize the BPP-V and BP-IV epitope peptides.…”

Section: Discussionmentioning

confidence: 99%

“…Mouse serum samples were collected through tail vein from each group on days 1, 3,5,7,9,11,13,15,17,19,21,23,25,27, and 29 after immunization, and the anti-HA (IgG) antibody were determined to evaluate whether the mice consistently produce antibody. On days 7, 14, and 21 after immunization, mice serum samples were also collected through tail vein, and anti-HA antibody (IgG), IgG1, and IgG2a levels were determined by ELISA as previously described (22).…”

Section: Detection Of Specific Antibodiesmentioning

confidence: 99%

“…The spleens of mice from each group were collected on days 7, 14, and 21 after immunization and the splenic lymphocyte proliferation assay was performed using the MTT method (17). Briefly, splenic lymphocyte suspensions (2×10 6 cells/mL) were dispersed and incubated in 96-well plates (100 mL per well), and 50 mL of ConA (40 mg/mL) or LPS (1 mg/mL) was added to each well and incubated at 37°C and 5% CO 2 for 48 h. Then, 20 mL of MTT (5 mg/mL) was added to each well for 4 h, followed by the addition of 100 mL of DMSO while shaking for 10 min.…”

Section: Lymphocyte Proliferation Assaymentioning

confidence: 99%

“…The OD was read at 570 nm, and the experiments were repeated in triplicate. 3,5,7,9,11,13,15,17,19,21,23,25,27, and 29 after immunization. The levels of anti-HA (IgG), IgG1, IgG2a, IL-4, and IFN-g were detected on days 7, 14, and 21 after immunization.…”

Section: Lymphocyte Proliferation Assaymentioning

confidence: 99%

“…Our researches have shown that BPP-V and BP-IV are used as immune adjuvants in combination with the commercial H9N2 AIV inactivated vaccine to enhance humoral and cellular immune responses (17,18). Then, BPP-V and BP-IV were bound to the H9N2 AIV epitope peptide to form BPP-V epitope peptide and BP-IV epitope peptide and studied as molecular immune adjuvants.…”

Section: Introductionmentioning

confidence: 99%

See 4 more Smart Citations

Development of PDA Nanoparticles for H9N2 Avian Influenza BPP-V/BP-IV Epitope Peptide Vaccines: Immunogenicity and Delivery Efficiency Improvement

et al. 2021

Self Cite

View full text Add to dashboard Cite

The protection of current influenza vaccines is limited due to the viral antigenic shifts and antigenic drifts. The universal influenza vaccine is a new hotspot in vaccine research that aims to overcome these problems. Polydopamine (PDA), a versatile biomaterial, has the advantages of an excellent biocompatibility, controllable particle size, and distinctive drug loading approach in drug delivery systems. To enhance the immunogenicities and delivery efficiencies of H9N2 avian influenza virus (AIV) epitope peptide vaccines, PDA nanoparticles conjugated with the BPP-V and BP-IV epitope peptides were used to prepare the nano BPP-V and BP-IV epitope peptide vaccines, respectively. The characteristics of the newly developed epitope peptide vaccines were then evaluated, revealing particle sizes ranging from approximately 240 to 290 nm (PDI<0.3), indicating that the synthesized nanoparticles were stable. Simultaneously, the immunoprotective effects of nano BPP-V and BP-IV epitope peptide vaccines were assessed. The nano BPP-V and BP-IV epitope vaccines, especially nano BP-IV epitope vaccine, quickly induced anti-hemagglutinin (HA) antibody production and a sustained immune response, significantly promoted humoral and cellular immune responses, reduced viral lung damage and provided effective protection against AIV viral infection. Together, these results reveal that PDA, as a delivery carrier, can improve the immunogenicities and delivery efficiencies of H9N2 AIV nano epitope vaccines, thereby providing a theoretical basis for the design and development of PDA as a carrier of new universal influenza vaccines.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Detection Of Specific Antibodiesmentioning

confidence: 99%

Section: Lymphocyte Proliferation Assaymentioning

confidence: 99%

Section: Lymphocyte Proliferation Assaymentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Development of PDA Nanoparticles for H9N2 Avian Influenza BPP-V/BP-IV Epitope Peptide Vaccines: Immunogenicity and Delivery Efficiency Improvement

et al. 2021

Self Cite

View full text Add to dashboard Cite

show abstract

Antimicrobial peptide PMAP‐37 analogs: Increasing the positive charge to enhance the antibacterial activity of PMAP‐37

Zhou

Chen

Liu

et al. 2019

Journal of Peptide Science

View full text Add to dashboard Cite

Bacterial resistance induced by the use of antibiotics has provided a chance for the development of antimicrobial peptides (AMPs), and modification of AMPs to enhance the antibacterial activity or stability has become a research focus. PMAP‐37 is an AMP isolated from porcine myeloid marrow, and studies on its modification have not yet been reported. In this study, three PMAP‐37 analogs named PMAP‐37(F9‐R), PMAP‐37(F34‐R), and PMAP‐37(F9/34‐R) were designed by residue substitution to enhance the positive charge. The antimicrobial activity of PMAP‐37 and its analogs in vitro and in vivo were detected. The results showed that compared with PMAP‐37, PMAP‐37(F9‐R) and PMAP‐37(F9/34‐R) exhibited antibacterial activity against S. flexneri CICC21534. Although PMAP‐37(F34‐R) had no antibacterial activity against S. flexneri CICC21534, its minimal inhibitory concentrations (MICs) were significantly lower than those of PMAP‐37 against most bacterial strains. Besides, all PMAP‐37 analogs were pH stable, retaining stable antibacterial activity after treatment with solution from pH 2 to pH 8/9. In addition, the PMAP‐37 analogs displayed increased thermal stability, and PMAP‐37(F34‐R) retained >60% antibacterial activity after boiling for 2 hours. Furthermore, the PMAP‐37 analogs exhibited impressive therapeutic efficacy in bacterial infections by reducing bacterial burden and inflammatory damage in the lung and liver, resulting in a reduction in mortality. Notably, the therapeutic effect of PMAP‐37(F34‐R) was comparable to that of ceftiofur sodium, and even superior to antibiotics in L. monocytogenes CICC21533 infection model. In conclusion, the PMAP‐37(F34‐R) may be a candidate for the treatment of bacterial infections in the clinic.

show abstract

Antimicrobial Activity of the Antibacterial Peptide PMAP-GI24 and Its Analogs

Liu

Yan

Chai³

et al. 2020

Int J Pept Res Ther

View full text Add to dashboard Cite

Adjuvant Activity of Bursal Pentapeptide-(III-V) in Mice Immunized with the H9N2 Avian Influenza Vaccine

Cited by 11 publications

References 0 publications

Development of PDA Nanoparticles for H9N2 Avian Influenza BPP-V/BP-IV Epitope Peptide Vaccines: Immunogenicity and Delivery Efficiency Improvement

Development of PDA Nanoparticles for H9N2 Avian Influenza BPP-V/BP-IV Epitope Peptide Vaccines: Immunogenicity and Delivery Efficiency Improvement

Antimicrobial peptide PMAP‐37 analogs: Increasing the positive charge to enhance the antibacterial activity of PMAP‐37

Antimicrobial Activity of the Antibacterial Peptide PMAP-GI24 and Its Analogs

Contact Info

Product

Resources

About